Thirty-seven U.S. states and the District of Columbia will get $68.5 million from London-based AstraZeneca to settle out-of-court allegations that it deceptively marketed its anti-psychotic drug
Seroquel. That settlement is separate from a $520 million agreement reached last year with the U.S.
AstraZeneca promoted the drug, approved for schizophrenia and bipolar disorder, for
dementia, depression and anxiety in violation of federal drug rules, according to the states, which also said the company hadn't adequately represented the drug's potential side effects, such as high
blood sugar and diabetes.
Read the whole story at Bloomberg »